Robo.ai Inc. to Acquire Controlling Stake in Chinasky Car Trading FZE, Accelerating Commercialization of Intelligent Hardware Strategy
The transaction is intended to transform CCT's established trade network within the
Located in the
The Chief Executive Officer of Robo.ai stated that the acquisition of CCT represents a significant step in the Company's strategy to integrate virtual technologies with physical applications. He noted that realizing the commercial value of core robotic and automation technologies requires integration with physical carriers and circulation networks. He added that CCT provides not only stable cash flow but also a strategic logistical position, serving as a foundational node for the Company's global market expansion. Looking ahead, Robo.ai plans to assist CCT in expanding into high-value-added business segments, including automotive parts, after-sales services, and supply chain finance, to build a comprehensive smart asset operation platform.
About Chinasky Car Trading FZE
A subsidiary of the Canadian Jiacheng Group, Chinasky Car Trading FZE is an automotive import and export trading company located in the
About Robo.ai Inc.
Robo.ai Inc. (NASDAQ: AIIO) is a technology company dedicated to building a leading global artificial intelligence machine economy platform. Its mission is to integrate "AI Software, Intelligent Hardware, and Smart Assets" to construct a unified AI operating system and an ecosystem empowered by blockchain, pioneering an intelligent future.
This press release includes "forward-looking statements" as defined in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/roboai-inc-to-acquire-controlling-stake-in-chinasky-car-trading-fze-accelerating-commercialization-of-intelligent-hardware-strategy-302697037.html
SOURCE Robo.ai Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
- Erasca prices upsized stock offering at $17.50 per share
- Edgewise sells muscular dystrophy drug to Servier for up to $2.65B
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share